Dr. Kao Shung-te (middle) of China Medical University Hospital and Dr. Houng Jer-yiing (left) of I-Shou University Medical School presented the study results of the randomized double-blind clinical trial and the bioavailability of Antromax in different dosages forms, respectively.
Agritechph.com | Antrodia cinnamomea has been approved by the US Food and Drug Administration as a new dietary ingredient | Greenyn Biotechnology Corporation held a seminar on April 12th titled “The international growth of Taiwan’s Antrodia cinnamomea and its clinical application,” where they declared Antromax’s non-objection by the USFDA NDI. It was a fantastic achievement for Greenyn, and it would undoubtedly encourage the Antrodia industry to invest more money in the US sector.
The edible fungus A. cinnamomea grows on the endangered Cinnamomum kanehirae tree, which is only found in Taiwan. This native fungus has long been used to treat liver problems, hangovers, exhaustion, and boost immunity. This miraculous fungus was given the name “Ruby of Taiwan.”
We are surprised that we were able to receive the USFDA NDI No. 1170 notification without opposition for Antromax for marketing in the United States this time,” said Luo Hsuan, Greenyn’s CEO. Since A. cinnamomea is unknown in the western world, obtaining such notification has been difficult in the past. Its safety records, eating and application history are all restricted. “It is a big achievement for us, and the timing is ideal for us to enter the global market. We sincerely hope that Taiwan’s A. cinnamomea industry will seize this opportunity to expand globally “Luo Hsuan was also added.
A. cinnamomea is rare and grows slowly in the wild, according to Dr. Hsu Pang-kuei, Geeenyn’s R&D director. Since the tree Cinnamomum kanehirae is covered under plant conservation laws, you must wait three years before it is fully grown for medicinal purposes. It is also impossible to increase production/cultivate indoors. Fortunately, we can cultivate Antromax “A. cinnamomea mycelia” with active ingredients identical to the fully grown in just 3 months thanks to Greenyn’s solid-state fermentation technology. This proprietary fermentation process will not only help to preserve the tree, but it will also reduce the cost of production, allowing the general public to enjoy this fresh, organic food at a fair cost.
Antrodia cinnamomea appears to be effective as an adjuvant therapy in clinical trials.
Dr. Kao Shung-te, Attending Physician of China Medical University Hospital, presented the results of Antromax in the clinical adjuvant treatment of hepatitis B during the seminar. “Antromax has been discovered to have an adjuvant treatment benefit when paired with hepatitis B medication in medical trials. The liver function indices have increased, and the biochemical values in blood and urine have not changed.”
Furthermore, Dr. Houng Jer-yiing, Associate Dean of the I-Shou University Medical School, reported that Antromax’s bioavailability in various dosage forms has similar adjuvant effects, such as lowering liver function indexes, liver fat accumulation, and alcohol-related liver injuries, as well as increasing antioxidant enzyme activity.
Greenyn’s facility in the Central Taiwan Science Park is designed to international standards and has a capacity of up to 12 metric tons per year, which is adequate for global markets. “At the moment, we will concentrate on the US and European markets,” Dr. Hsu says, “but we will start promoting in Asia in the future, such as Korea, Southeast Asian countries, and Australia.” Greenyn is proud to lead Taiwan’s biotech industry in promoting A. cinnamomea in the US markets, which has a demand worth USD 9.6 billion. It is expected that the health benefits of A. cinnamomea to the rest of the world during Covid-19 would provide Taiwan with yet another source of pride.
